Additional studies also reveal that pharmacological intervention of mGluR activation can rescue the FXS phenotype in the Fmr1 mouse model suggesting a therapeutic role for inhibitors of mGluR activity- specifically type 1 and type 5 receptor activity (Dölen et al., 2007; Michalon et al., 2012; Ronesi et al., 2012). Here, FMR1 is linked to fragile X syndrome.